Embedded Files
DelveInsight’s “Presbyopia Pipeline Insight 2025” report delivers in-depth information on over 10 companies and over 10 pipeline drugs in the Presbyopia treatment landscape. It encompasses profiles of Presbyopia pipeline drugs, including those in clinical and nonclinical phases. Additionally, it evaluates Presbyopia pipeline therapies by product category, development stage, administration method, and molecular structure. It also spotlights discontinued pipeline products in this field. Explore the newest medications and therapeutic approaches in the Presbyopia Pipeline. Access DelveInsight's thorough report immediately!@ Presbyopia Pipeline Outlook
Key Highlights from the Presbyopia Pipeline Report
In September 2025, Ocuphire Pharma Inc. disclosed a phase 3 trial assessing the safety and effectiveness of Nyxol (Phentolamine Ophthalmic Solution 0.75%) alone and combined with low-dose Pilocarpine Hydrochloride Ophthalmic Solution 0.4% for individuals with Presbyopia. DelveInsight’s Presbyopia Pipeline report illustrates a vibrant arena with over 10 active entities advancing over 10 pipeline treatments for Presbyopia management.
Leading Presbyopia firms include Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio, and more.
Promising Presbyopia Pipeline Therapies encompass Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Pilocarpine HCl, UNR844-Cl, CSF-1, AGN-190584, Pilocarpine Ophthalmic, Aceclidine, Brimonidine, and others. Remain informed with the latest Presbyopia pipeline developments.
Gain knowledge on clinical studies, novel therapies, and prominent companies in Presbyopia @ Presbyopia Treatment Drugs
The Presbyopia Pipeline Report offers a condition summary, pipeline overview, and evaluation of major pipeline therapies in this area. The Presbyopia Pipeline Report also emphasizes unmet requirements related to Presbyopia.
Presbyopia Overview Presbyopia represents a widespread, age-linked refractive disorder causing a progressive loss in the eye's capacity to focus on close objects, usually evident in the early to mid-40s and worsening over time. The issue stems mainly from age-related alterations in the crystalline lens, which loses flexibility and thickens due to protein bonding and densification. This diminished lens adaptability hinders effective shape-changing during accommodation, the mechanism allowing the eye to concentrate on nearby items.
Presbyopia Emerging Drugs Profile LNZ100: Lenz Therapeutics LNZ100 consists of a preservative-free, single-use, daily eye drop with aceclidine, a targeted muscarinic receptor activator. It functions by narrowing the pupil, generating a pinhole effect that enhances close-up vision. In contrast to other pupil-narrowing substances, aceclidine features a distinct mode of action that separates the miotic impact from ciliary muscle activation, minimizing the chance of nearsighted shift and associated forehead discomfort. This enables LNZ100 to offer a wide patient base with a sustained and potent solution for presbyopia, marked by lens stiffening and reduced near vision with aging. The US Food and Drug Administration (FDA) has approved the Company’s New Drug Application (NDA) for LNZ100 targeting presbyopia. Presently, the medication is in the registration phase of its clinical trial for presbyopia treatment.
GLK-302: Glaukos Corporation Glaukos Corporation is advancing GLK-302, a sterile ophthalmic topical ointment featuring pilocarpine as the key component, aimed at presbyopia. GLK-302 is formulated for eyelid application, facilitating pilocarpine absorption via the skin to the eye. Its action involves pilocarpine, a muscarinic acetylcholine receptor stimulant, targeting M3 and M1 receptors in the eye to induce pupil contraction and expand the focus range, thus boosting near visual sharpness in presbyopic individuals without markedly impairing far vision. Currently, the drug is in Phase II of its clinical trial for presbyopia.
The Presbyopia Pipeline Report Provides Insights into- The report delivers comprehensive details on organizations developing therapies for Presbyopia, including the total therapies per company. It examines various therapeutic candidates divided into early, mid, and late development stages for Presbyopia care. Presbyopia Companies are engaged in specialized therapeutic development, with active and inactive (dormant or halted) initiatives. Presbyopia Drugs in progress, categorized by development phase, delivery route, target receptor, standalone or combined treatment, distinct action mechanisms, and molecular category. In-depth review of partnerships (corporate-corporate and corporate-academic), licensing deals, and funding details for upcoming Presbyopia market growth. Discover innovative therapies and trials in the Presbyopia Pipeline.
Obtain DelveInsight's comprehensive report now!@ New Presbyopia Drugs
Presbyopia Companies Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio, and others.
Presbyopia Pipeline Report provides the therapeutic evaluation of pipeline drugs by the Route of Administration. Products are grouped under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Oral Parenteral Subcutaneous Topical Transdermal
Presbyopia Products are grouped under various Molecule types such as Oligonucleotide Peptide Small molecule
Reveal the future of Presbyopia Treatment. Learn about novel medications, Presbyopia Pipeline advancements, and key companies through DelveInsight's expert review @ Presbyopia Market Drivers and Barriers
Scope of the Presbyopia Pipeline Report Coverage- Global
Presbyopia Companies- Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio and others.
Presbyopia Pipeline Therapies- Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Pilocarpine HCl, UNR844-Cl, CSF-1, AGN-190584, Pilocarpine Ophthalmic, Aceclidine, Brimonidine and others.
Presbyopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Presbyopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the most current information on Presbyopia Pipeline Therapies and clinical trials. Download DelveInsight's detailed pipeline report today!@ Presbyopia Companies, Key Products and Unmet Needs
Table of Contents
Table of Contents
Introduction
Executive Summary
Presbyopia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Presbyopia – DelveInsight’s Analytical Perspective
Late Stage Products (Registration)
LNZ100: Lenz Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
GLK-302: Glaukos Corporation
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug Name: Company Name
Preclinical Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Presbyopia Collaborations Assessment- Licensing / Partnering / Funding
Presbyopia Unmet Needs
Presbyopia Market Drivers and Barriers
Appendix
About Us
DelveInsight stands as a premier healthcare-oriented market research and advisory firm, equipping clients with premium market intelligence and analysis for strategic decision-making. Boasting a cadre of seasoned industry professionals and profound expertise in life sciences and healthcare, we provide tailored research solutions and insights to clients worldwide. Reach out to us for top-tier, precise, and timely intelligence to lead the growth trajectory.
Contact Us
Kanishk
kkumar@delveinsight.com
Page updated
Report abuse